OSE Immunotherapeutics is ramping up its strategic realignment to progress its late-stage value drivers, Lusvertikimab and Tedopi®. These key assets are currently at advanced stages of development and hold significant promise for the company. The decision to prioritize these programs underscores OSE Immunotherapeutics' commitment to maximizing their potential and enhancing shareholder value. This move comes as part of the company's overarching efforts to streamline its focus and allocate resources efficiently. Lusvertikimab and Tedopi® represent important pillars in OSE Immunotherapeutics' portfolio, with substantial opportunities for growth and success.